94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
REVIEW article
Front. Med.
Sec. Gene and Cell Therapy
Volume 12 - 2025 | doi: 10.3389/fmed.2025.1550527
This article is part of the Research Topic Access to Immune Effector Cell Therapies View all 4 articles
CELL THERAPIES FOR IMMUNE-MEDIATED DISORDERS
Provisionally accepted
Natalia Wiewiórska-Krata 1,2
Bartosz Foroncewicz 2,3
Krzysztof Mucha 2,3,4
Radoslaw Zagozdzon 1,3,4*- 1 Laboratory of Cellular and Genetic Therapies, Center for Preclinical Research, Medical University of Warsaw,, Warsaw, Poland
- 2 ProMix Center (ProteogenOmix in Medicine), Department of Clinical Immunology, Medical University of Warsaw, Warsaw, Poland, Warsaw, Masovian, Poland
- 3 Department of Transplantology, Immunology, Nephrology and Internal Diseases, Medical University of Warsaw, Warsaw, Masovian, Poland
- 4 Institute of Biochemistry and Biophysics, Polish Academy of Sciences, Warsaw, Masovian, Poland
Immune-mediated disorders are a broad range of diseases, arising as consequence of immune defects, exaggerated/misguided immune response or a mixture of both conditions. Their frequency is on a rise in the developed societies and they pose a significant challenge for diagnosis and treatment. Traditional pharmacological, monoclonal antibody-based or polyclonal antibody replacement-based therapies aiming at modulation of the immune responses give very often dissatisfactory results and/or are burdened with unacceptable adverse effects. In recent years, a new group of treatment modalities has emerged, utilizing cells as living drugs, especially with the use of the up-to-date genetic engineering. These modern cellular therapies are designed to offer a high potential for more targeted, safe, durable, and personalized treatment options. This work briefly reviews the latest advances in the treatment of immune-mediated disorders, mainly those related to exaggeration of the immune response, with such cellular therapies as hematopoietic stem cells (HSCs), mesenchymal stem cells (MSCs), regulatory T cells (Tregs), chimeric antigen receptor (CAR) T cells and others. We highlight the main features of these therapies as new treatment options for taming the dysregulated immune system. Undoubtfully, in near future such therapies can provide lasting remissions in a range of immune-mediated disorders with reduced treatment burden and improved quality of life for the patients.
Keywords: Cell therapies, Immune disorders, Transplantation, Regenerative Medicine, Treg cells
Received: 23 Dec 2024; Accepted: 17 Feb 2025.
Copyright: © 2025 Wiewiórska-Krata, Foroncewicz, Mucha and Zagozdzon. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Radoslaw Zagozdzon, Laboratory of Cellular and Genetic Therapies, Center for Preclinical Research, Medical University of Warsaw,, Warsaw, Poland
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.